SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

ProMIS Neurosciences Inc.
Date: March 23, 2026 · CIK: 0001374339 · Accession: 0000000000-26-002902

Offering / Registration Process Regulatory Compliance

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-294408

Date
March 23, 2026
Author
Neil Warma
Form
UPLOAD
Company
ProMIS Neurosciences Inc.

Letter

March 23, 2026 Neil Warma Chief Executive Officer ProMIS Neurosciences Inc. Suite 200, 1920 Yonge Street Toronto, Ontario M4S 3E2 Re:ProMIS Neurosciences Inc. Registration Statement on Form S-3 Filed March 18, 2026 File No. 333-294408 Dear Neil Warma: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Adam Johnson

Show Raw Text
March 23, 2026
Neil Warma
Chief Executive Officer
ProMIS Neurosciences Inc.
Suite 200, 1920 Yonge Street
Toronto, Ontario M4S 3E2
Re:ProMIS Neurosciences Inc.
Registration Statement on Form S-3
Filed March 18, 2026
File No. 333-294408
Dear Neil Warma:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Adam Johnson